|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.8937 - 5.1000|
|52 Week Range||3.4580 - 10.4404|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
JWC AND TERRASCEND SIGN MUTUALLY BENEFICIAL PURCHASE AND SUPPLY CONTRACT TORONTO , Aug.15, 2019 /CNW/ - Canopy Rivers Inc. (" Canopy Rivers " or the " Company" ) (TSXV: RIV) (OTC: CNPOF) ...
OTCQX: TRSSF), pursuant to which the Corporation agreed to provide dry cannabis flower and cannabis oils to TerrAscend (the “Agreement”). It is anticipated that the Purchaser will list the product acquired from JWC under the Agreement for sale on its online medical sales platform, the Solace Health online marketplace, once inaugural product inventories have been received. With this Agreement, JWC will have access to two of the largest medical store fronts in Canada.
OTCQX: TRSSF) ("TerrAscend" or the "Company"), the first and only cannabis company licensed for sales in Canada, the US, and the EU, today announced that it has completed its first international shipment of dry cannabis flower to its German distribution partner iuvo Therapeutics GmbH ("iuvo"). The shipment was made from TerrAscend's EU GMP certified manufacturing facility in Mississauga, Ontario, Canada. As the Company ships additional product to Germany in partnership with iuvo, it will continue to expand its footprint in Europe and other international markets. The Company looks forward to providing investors with updates on such expansion activities. TerrAscend and iuvo, respectively were granted an Export Permit by Health Canada, under the Cannabis Act, and an Import Authorization from Germany's Federal Institute for Drugs and Medical Devices, following the issuance of the Company's EU Good Manufacturing Practice ("GMP") certificate on April 29, 2019. TerrAscend is one of only six companies with a GMP certified cannabis facility.
OTCQX: TRSSF) ("TerrAscend" or "the Company"), today announced that it will release its second quarter 2019 financial results on Thursday, August 22nd, 2019 at approximately 8:00 a.m. (ET). Financial results and analyses will be available on the Company's website (www.terrascend.com) and SEDAR (www.sedar.com). As the first North American Operator (NAO), with scale operations in both Canada and the US, the Company participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use.
LONDON, ON, Aug. 7, 2019 /CNW/ - Indiva Limited (the "Company" or "Indiva") (TSXV:NDVA.V - News) (OTCQX:NDVAF - News) and TerrAscend (CSE:TER) (OTCQX:TRSSF - News) are pleased to announce the signing of an agreement to partner on an extraction services program (the "Agreement"). Under the terms of the Agreement, Indiva will provide TerrAscend with extraction and refinement support at its state-of-the-art facility in London, Ontario.
TORONTO, Aug. 6, 2019 /CNW/ - Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSXV:RIV.V - News) (OTC:CNPOF - News) is pleased to announce its portfolio company, TerrAscend Corp. ("TerrAscend") (CSE:TER.CN - News) (OTCQX:TRSSF - News), has signed a definitive agreement to acquire Ilera Healthcare ("Ilera"), a vertically-integrated cannabis cultivator, processor, and dispensary operator in Pennsylvania. Ilera's state-of-the-art, fully integrated seed-to-sale operations adds to TerrAscend's growing global footprint, currently spanning multiple U.S. states, Canada and the European Union. "TerrAscend's rapid expansion in the U.S. has been driven by strategic, accretive acquisitions of quality operators with strong track records of success," said Narbe Alexandrian, President and CEO of Canopy Rivers.
--- Ilera's current revenue run-rate is over US$43 million 1, up from total sales in 2018 of less than US$8 million 1. --- State-of-the-art, fully integrated seed-to-sale operator in Pennsylvania adds to TerrAscend's global portfolio of operations across multiple U.S. States, Canada and the EU. --- Ilera's team members will continue in their current roles and join TerrAscend's rapidly expanding US operations.
OTCQX: TRSSF) ("TerrAscend" or "the Company"), the first and only cannabis company licensed for sales in Canada, the US, and Europe is pleased to congratulate the team at PharmHouse Inc. ("PharmHouse") on securing a cannabis cultivation licence from Health Canada. The licence allows PharmHouse to begin cultivating and supplying cannabis from its 1.3 million square foot greenhouse (the "Facility") located in Leamington, Ontario.
TORONTO , July 8, 2019 /CNW/ - Canopy Rivers Inc. (" Canopy Rivers " or the " Company ") (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company TerrAscend Corp. (" TerrAscend ...
OTCQX: TRSSF) ("TerrAscend" or the "Company") today announced that its subsidiary, TerrAscend Canada, has received an amendment to its license from Health Canada to allow it to sell cannabis oils from its EU-GMP certified facility in Mississauga, Ontario. Sales of TerrAscend's cannabis oils will begin immediately through its medical marketplace, Solace Health (www.solacehealth.com), and to the Canadian adult use market in the coming weeks. The Company is also pursuing export of its oils to international medical markets and will share news of these milestones as it achieves them.
OTCQX: TRSSF) ("TerrAscend" or the "Company") has closed a series of transactions to acquire the California operations of the award-winning retail dispensary brand known as "The Apothecarium" for consideration comprised of US$36.8 million in cash and proportionate voting shares in the equity of TerrAscend equivalent to 6.7mm common shares of the Company. The transactions include three entities operating the San Francisco locations of The Apothecarium, two additional retail locations, and Valhalla Confections, a leading provider of premium edible products.
OTCQX: TRSSF) ("TerrAscend" or the "Company") is pleased to announce that the nominees set forth in the Company's management information circular dated April 24, 2019, Mr. Craig Collard, Mr. Richard Mavrinac, Dr. Michael Nashat, Ms. Lisa Swartzman and Mr. Jason Wild, were elected as directors of the Company at the annual meeting of shareholders held today (the "Meeting"). At the Meeting, shareholders also approved the re-appointment of MNP LLP as the auditor of the Company and the authorization of the Company's board of directors to fix the auditor's remuneration.
TORONTO, May 28, 2019 /CNW/ - TerrAscend Corp. (CSE:TER;OTCQX:TRSSF) ("TerrAscend" or the "Company") has completed its previously announced upsized non-brokered private placement (the "Private Placement") with orders totaling approximately $69 million. The Company issued 9,026,034 common shares in the Private Placement at the previously announced price of $7.64. All members of the Company's leadership team participated in the Offering, including a US$18.4 million lead order from funds advised by JW Asset Management, LLC and affiliated entities. For further details concerning the Private Placement, please refer to the Company's news release dated May 7, 2019. The Company has agreed to pay a cash finder's fee based on subscriptions for the Private Placement arranged by certain finders, led by Clarus Securities Inc.
OTCQX: TRSSF) ("TerrAscend" or "the Company") today reported financial results for the first quarter ending March 31, 2019. Financial results and analyses are available on the Company's website (www.terrascend.com) and SEDAR (www.sedar.com).
TORONTO, May 3, 2019 /CNW/ - Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSXV:RIV.V - News) (OTC:CNPOF - News) congratulates its portfolio company TerrAscend Corp. ("TerrAscend") (CSE:TER.CN - News) (OTCQX:TRSSF - News) on its announcement yesterday that its facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice ("GMP") certificate in accordance with the rules governing medicinal products in the European Union ("EU"). Only medical cannabis from EU GMP certified facilities, or the equivalent, may be sold in the EU. The regulatory approach has been led by several of the larger EU countries and as such, pharmaceutical grade controls in production were an established requirement from the onset of medical cannabis legalization.
OTCQX: TRSSF) ("TerrAscend" or the "Company") today announced that its manufacturing facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice ("GMP") certificate in accordance with the rules governing medicinal products in the European Union ("EU"). The EU GMP certification was awarded by the responsible agency, Arzneimittelbehörde, in North Rhine-Westphalia, Germany. Additionally, the Company has entered a comprehensive sales and distribution agreement with iuvo Therapeutics GmbH ("iuvo"), a German pharmaceutical wholesaler with a cannabis-specific import and distribution license.
OTCQX: TRSSF) ("TerrAscend" or "the Company") today announced the recent appointment of Lisa Swartzman to its Board of Directors. Ms. Swartzman is an accomplished C-suite executive who brings over 20 years of experience in large and mid-market publicly traded organizations. Headquartered in Newmarket, Ontario, AirBoss operates facilities in Canada and the United States.
TORONTO, April 24, 2019 /CNW/ - TerrAscend Corp. (CSE:TER OTCQX:TRSSF) ("TerrAscend" or the "Company") today reported financial results for the fourth quarter ending December 31, 2018. Financial results and analyses are available on the Company's website (www.terrascend.com) and SEDAR (www.sedar.com). For the three months ended December 31, 2018, revenue totaled $5.0 million, up from $1.8 million in the third quarter of 2018 and $0.0 million in the fourth quarter of 2017.
Deal size is increased from previously announced US$20 - $30 million due to strong investor demand /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ TORONTO , April 23, 2019 ...
TerrAscend provides quality products, brands, and services to the global cannabinoid market. The Company participates in the medical and legal adult use market in Canada and in US states where cannabis has been legalized for therapeutic or adult use. Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to cultivate, distribute or possess cannabis in the United States. Furthermore, financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.
The Company expects to open new Apothecarium locations in Berkeley, California and Philipsburg, New Jersey as well as a fully vertically integrated cultivation, extraction and processing facility in Boonton, New Jersey in Q4 2019. The Company has not included revenue from these operations in 2019 guidance. "We are seeing the results of the foundation we laid in 2018. Our team is focused on operational excellence in our facilities across North America, continuing to procure new licenses across the US through greenfield license applications and strategic acquisitions of existing operations. On behalf of all of the employees of TerrAscend, we pledge to continue our hard work and efforts in our goal of exceeding patient, customer and stakeholder expectations." said Matthew Johnson, President of TerrAscend Corp., and TerrAscend USA, Inc.
OTCQX: TRSSF) ("TerrAscend"), a leading North American Operator with a strong presence across the entire cannabis value chain, will attend GMP Securities' 2019 Cannabis Conference to be held April 16, 2019 at the Ritz-Carlton Hotel in Toronto. TerrAscend President Matthew Johnson will share highlights of TerrAscend's strategy and operations, including plans for expansion through organic growth, acquisitions, and partnerships in North America and globally. TerrAscend operates a number of synergistic businesses, including Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products, Ascendant Laboratories Inc., a biotechnology and licensing Company committed to the continuous improvement of cannabinoid expressing plants, and Solace RX Inc., a proposed drug preparation premises focused on the development of novel formulations and dosage forms.
It's a no-go for recreational marijuana in the Garden State for now. And several marijuana stocks are feeling the sting of the state's delay.
Completed capital reorganization with the continued support of Canopy Growth Corp. (TSX:WEED.TO - News) (NYSE: CGC), Canopy Rivers Corp. (TSXV:RIV.V - News) and funds controlled by Jason Wild, Chairman of the Company, allowing the Company to pursue US expansion. In addition, the company will be opening its first East Coast Apothecarium location in Philipsburg, NJ in Q4 2019. The Company continued to drive sales for its adult-use brand, Haven St. Premium Cannabis, a top-10 selling brand in the five Canadian provincial jurisdictions where it is sold.